• Join
  • Login
  • Contact

Search abstracts

Risks and benefits of FDA's fast-track approval

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Presentation
  • By: JAIN, Prateek (Decision Resources Group, India)
  • Abstract:

    The US Food and Drug Administration (FDA) has been pushing new therapies to the market faster than ever. There are four expedited pathways; fast-track designation, accelerated approval, priority review, and breakthrough therapy designation (BTD). These processes facilitate the drug development by expediting the review process by cutting down the


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses